A phase II clinical trial of sorafenib in androgen-independent prostate cancer.

  title={A phase II clinical trial of sorafenib in androgen-independent prostate cancer.},
  author={William L. Dahut and Charity D. Scripture and Edwin M. Posadas and Lokesh Jain and James L. Gulley and Philip M. Arlen and John Joseph Wright and Yunkai Yu and Liang Cao and Seth Steinberg and Jeanny B. Aragon-Ching and J{\"u}rgen Venitz and Elizabeth O Jones and Clara C. Chen and William D. Figg},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  volume={14 1},
PURPOSE To determine if sorafenib is associated with a 4-month probability of progression-free survival, which is consistent with 50%, as determined by clinical, radiographic, and prostate-specific antigen (PSA) criteria in patients with metastatic androgen-independent prostate cancer (AIPC). EXPERIMENTAL DESIGN Patients with progressive metastatic AIPC were enrolled in an open-label, single-arm phase II study. Sorafenib was given continuously at a dose of 400 mg orally twice daily in 28-day… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 1 time. VIEW TWEETS


Publications citing this paper.
Showing 1-10 of 78 extracted citations

Angiogenesis inhibitors in the treatment of prostate cancer

Journal of hematology & oncology • 2010
View 3 Excerpts
Highly Influenced

Similar Papers

Loading similar papers…